2015-2016 Pilot Project: Effects of Electronic Cigarette Use on the Human Lung

Most electronic cigarettes (e-cigs) contain a nicotine-based liquid that is vaporized or inhaled. Because manufacturers present e-cigs as trendy, acceptable, a method to quit smoking and possibly a healthier alternative to cigarette smoking, the e-cig market has been growing rapidly; despite this, and limited FDA oversight, their health risks are largely unknown. The goal of this study is to investigate toxic effects of e-cig use on the human lungs and airways. This study will provide useful feasibility data to directly assess e-cig toxicity.

Project Leader

Min-Ae Song, PhD, Post-doctoral Researcher, Comprehensive Cancer Center, The Ohio State University

Mentor

Peter Shields, MD, Professor, College of Medicine, Deputy Director, Comprehensive Cancer Center, The Ohio State University

Other Investigators

Mahmoud H. Abdel-Rasoul, MS, MPH, Biostatistician, Center for Biostatistics, The Ohio State University

Amy M. Lehman, MAS, Senior Biostatistician, Center for Biostatistics, The Ohio State University

Patrick Nana-Sinkam, MD, Associate Professor, College of Medicine, Co-Director Research Programs in the Division of Pulmonary Allergy, Critical Care and Sleep Medicine, The Ohio State University 

Larry S. Schlesinger, MD, Chair, Department of Microbial Infection and Immunity, Saslaw Professor of Internal Medicine, Professor of Molecular Virology, Immunology, and Medical Genetics and Microbiology, The Ohio State University

Mark D. Wewers, MD, Professor and Physician, Pulmonary, Allergy, Critical Care & Sleep, College of Medicine, The Ohio State University 

 

The Ohio State University, Center of Excellence for Regulatory Tobacco Science (OSU-CERTS), is supported by grant number P50CA180908 from the National Cancer Institute, National Institutes of Health and Food and Drug Administration Center for Tobacco Products (CTP). The content in this website is solely the responsibility of OSU-CERTS and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration.